Antifungal Locks to Treat Fungal-related Central Line Infections
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the usefulness of antifungal lock therapy with
liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients
with catheter-related blood stream infections with fungal organisms, whose catheter has not
been removed because of the continuing critical need for central line access. The primary
group of potential patients will be those with intestinal insufficiency, including post-op
small bowel transplant recipients.
The recommendation of the Infectious Disease Society of America (IDSA) is to remove all
catheters with fungal infections and treat systemically for 14 days after the last positive
culture. However, in certain intestinal failure patients, removal of an infected line might
significantly reduce or eliminate intravenous (IV) access and create a life threatening
situation. Thus, the investigators' aim is to determine the usefulness of antifungal lock
therapy in intestinal failure patients whose catheter has not been removed. The
investigators' hope is to salvage central line catheters rather than to remove them.
Phase:
Phase 4
Details
Lead Sponsor:
Bill McGhee University of Pittsburgh
Collaborator:
Astellas Pharma Inc
Treatments:
Amphotericin B Antifungal Agents Liposomal amphotericin B Miconazole